MLKL and cholangiocarcinoma: Collectively, the results of the present study suggested that in contrast to MLKL, necroptosis activation may have anti-tumorigenic roles, and necroptosis-based treatment in combination with immune checkpoint inhibitors, could provide more efficient treatment for CCA patients.